National Cancer Institute; Notice of Meeting, 21965 [E8-8721]

Download as PDF Federal Register / Vol. 73, No. 79 / Wednesday, April 23, 2008 / Notices Name of Committee: National Cancer Institute Special Emphasis Panel; Innovative Technologies for Molecular Analysis of Cancer. Date: June 25–26, 2008. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Jeffrey E. DeClue, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8059, Bethesda, MD 20892–8329, 301–496–7904, decluej@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Centers of Excellence in Cancer Communication Research II. Date: July 15–17, 2008. Time: 7 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Gaithersburg Hilton, 620 Perry Parkway, Gaithersburg, MD 20877. Contact Person: Thomas M. Vollberg, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7142, Bethesda, MD 20892, 301–594–9582, vollbert@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 15, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–8609 Filed 4–22–08; 8:45 am] notify the Contact Person listed below in advance of the meeting. Name of Committee: National Cancer Institute Clinical Trials; Advisory Committee. Date: June 25, 2008. Time: 8 a.m. to 5 p.m. Agenda: Update on the progress of the implementation of the Clinical Trials Working Group and the Translational Research Working Group reports. Place: National Institutes of Health, Building 31, 31 Center Drive, 6th Floor, CWing, Conference Room 10, Bethesda, MD 20892. Contact Person: Sheila A. Prindiville, MD, Director, Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd., Suite 507, Bethesda, MD 20892, 301–451–5048, prindivs@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: April 16, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–8721 Filed 4–22–08; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute; Notice of Meeting mstockstill on PROD1PC66 with NOTICES National Institutes of Health Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Clinical Trials Advisory Committee. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should VerDate Aug<31>2005 16:58 Apr 22, 2008 Jkt 214001 National Center for Complementary & Alternative Medicine; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections PO 00000 Frm 00066 Fmt 4703 Sfmt 4703 21965 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Center for Complementary and Alternative Medicine Special Emphasis Panel. Date: June 16–17, 2008. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott Gaithersburg, Washingtonian Center, 204 Boardwalk Place, Gaithersburg, MD 20878. Contact Person: Peter Kozel, PhD, Scientific Review Officer, NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892–5475, 301–496–8004, kozelp@mail.nih.gov. Dated: April 16, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E8–8712 Filed 4–22–08; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; NEI Loan Repayment Program Applications. Date: May 13, 2008. Time: 1 p.m. to 3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Anne E. Schaffner, PhD, Scientific Review Administrator, Division of E:\FR\FM\23APN1.SGM 23APN1

Agencies

[Federal Register Volume 73, Number 79 (Wednesday, April 23, 2008)]
[Notices]
[Page 21965]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8721]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the National Cancer Institute Clinical Trials Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: National Cancer Institute Clinical Trials; 
Advisory Committee.
    Date: June 25, 2008.
    Time: 8 a.m. to 5 p.m.
    Agenda: Update on the progress of the implementation of the 
Clinical Trials Working Group and the Translational Research Working 
Group reports.
    Place: National Institutes of Health, Building 31, 31 Center 
Drive, 6th Floor, C-Wing, Conference Room 10, Bethesda, MD 20892.
    Contact Person: Sheila A. Prindiville, MD, Director, 
Coordinating Center for Clinical Trials, Office of the Director, 
National Cancer Institute, National Institutes of Health, 6120 
Executive Blvd., Suite 507, Bethesda, MD 20892, 301-451-5048, 
prindivs@mail.nih.gov.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: April 16, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
 [FR Doc. E8-8721 Filed 4-22-08; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.